miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo

Zhenfeng Duan1, Yan Gao1, Jacson Shen1

  • 1Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA, USA.

Molecular Oncology
|February 2, 2017
PubMed

Insights

MicroRNA-15b (miR-15b) downregulation is linked to multidrug resistance (MDR) in osteosarcoma. Restoring miR-15b levels can reverse chemotherapy resistance and improve patient survival in osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multidrug resistance (MDR) in osteosarcoma poses a significant clinical challenge.
  • The role of microRNAs (miRNAs) in osteosarcoma drug resistance is not well understood.

Purpose of the Study:

  • To identify and characterize human miRNAs regulating MDR in osteosarcoma.
  • To investigate the specific role of miR-15b in osteosarcoma MDR.

Main Methods:

  • MicroRNA microarray screening of MDR osteosarcoma cell lines.
  • Analysis of miR-15b expression in cell lines and patient tumor samples (TMA).
  • In vitro and in vivo studies using miR-15b mimics in mouse xenograft models.

Main Results:

  • miR-15b was significantly downregulated in MDR osteosarcoma cell lines.
  • miR-15b targets Wee1, and its inhibition partially reverses MDR in vitro.
  • In vivo administration of miR-15b mimics sensitized resistant cells to doxorubicin.
  • Low miR-15b expression correlated with poorer survival in osteosarcoma patients.

Conclusions:

  • Downregulation of miR-15b is associated with MDR in osteosarcoma.
  • Restoring miR-15b can overcome chemotherapy resistance in osteosarcoma.
  • miR-15b serves as a potential therapeutic target for overcoming MDR in osteosarcoma.